Clinical trials: HFpEF - Heart Failure With Preserved Ejection Fraction
Heart Failure With Normal Ejection Fraction
Renal Hemodynamics in Patients With HFpEF
Impaired renal function and heart failure with preserved ejection fraction (HFpEF) are two often co-existing medical conditions and are known to be associated with adverse cardiovascular outcome and increased mortality.
- Trial name
- NCT03672591
- Testing
- Renal clearance examination
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
This was a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure…
- Trial name
- NCT03037580
- Testing
- Oral treprostinil
- Where
- 82 sites in United States
- Volunteers
- 84 people
- Sponsor
- United Therapeutics
Heart Failure With Preserved Ejection Fraction, Diabetes Mellitus, Type 2
Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Metabolic Effects. (KETO-HFpEF-Metabolic)
Heart failure (HF) is among the most common causes of death in patients with type 2 diabetes (T2D). Ketones, 3-hydroxybutyrate (3-OHB), have shown to have beneficial effects in patients with hearth failure with reduced ejection…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Diabetes Mellitus, Type 2, Ketonemia
- Trial name
- NCT05159570
- Testing
- Ketone ester
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- University of Aarhus
Heart Failure With Preserved Ejection Fraction (HFpEF
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve.
- Trial name
- Rebalance-HF (NCT04592445)
- Testing
- Greater Splanchnic Nerve Ablation
- Where
- 26 sites in United States, Georgia
- Volunteers
- 150 people
- Sponsor
- Axon Therapies, Inc.
Heart Failure With Preserved Ejection Fraction (HFpEF
Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency
This study will investigate whether intravenous (IV) iron improves symptoms, exercise capacity, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency.
- Trial name
- ISLE HFpEF (NCT07643818)
- Testing
- Ferric Derisomaltose
- Where
- Jersey
- Volunteers
- 150 people
- Sponsor
- Government of Jersey
Heart Failure With Preserved Ejection Fraction
The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and…
- Trial name
- NCT04535726
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chongqing Medical University
Heart Failure with Mid-range Ejection Fraction, Heart Failure with Preserved Ejection Fraction
Spironolactone in the Treatment of Heart Failure
The purpose of this study is to determine whether the treatment of patients with HFmrEF and HFpEF at high risk of cardiovascular events with the mineralocorticoid receptor antagonist (MRA) spironolactone reduces a composite of…
- Trial name
- SPIRIT-HF (NCT04727073)
- Testing
- Experimental: Spironolactone
- Where
- 69 sites in Austria, France and 3 more
- Volunteers
- 743 people
- Sponsor
- Charite University, Berlin, Germany
Heart Failure, Heart Failure, Diastolic
RESPONDER-HF Trial
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
- Trial name
- NCT05425459
- Testing
- Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
- Where
- 61 sites in United States, Australia and 5 more
- Volunteers
- 750 people
- Sponsor
- Corvia Medical
Heart Failure With Preserved Ejection Fraction
Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction
Beta blockers have been used to reduce the mortality and heart failure rehospitalization in heart failure with reduced ejection fraction (HFrEF) patients in addition to ACEI/ARB, MRA, ivabradine and ARNI.
- Trial name
- NCT03948685
- Testing
- Carvedilol SR
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Yonsei University
Cardiovascular Disease, Cardiometabolic Diseases
Effects of a Specialized Diabetes and Heart Clinic and Detection of Unrecognized Heart Failure in People With Type 2 Diabetes and Cardiovascular Disease
The goal of this clinical trial is to investigate the effects of a specialized Cardio-Metabolic Clinic (CMC) in people with type 2 diabetes and established cardiovascular disease.
- Conditions
- Cardiovascular Disease, Cardiometabolic Diseases, Diabetes Type 2, Diabetes and Heart Failure
- Trial name
- NCT07878325
- Testing
- Cardio-Metabolic Clinic
- Where
- Denmark
- Volunteers
- 375 people
- Sponsor
- Odense University Hospital
Heart Failure With Normal Ejection Fraction
The Heart Failure With Preserved Ejection Fraction (HFpEF) Pathophysiology Study.
The study addresses the hypothesis that a gradual build-up in arterial resistance and microvascular endothelial dysfunction due to common comorbidities such as hypertension and diabetes mellitus, on top of age related vascular…
- Trial name
- IDENTIFY-HF (NCT03186833)
- Testing
- no intervention
- Where
- United Kingdom
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University Hospitals Coventry and Warwickshire NHS Trust
Congestive Heart Failure (CHF)
Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department
This study aims to evaluate whether the use of a 25 mg dose of empagliflozin compared to the 10 mg dose used would bring additional benefits in the improvement outcomes of the Kansas City Cardiomyopathy Questionnaire (KCCQ SST)…
- Trial name
- ADDEMFEP (NCT06683053)
- Testing
- empagliflozin
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- Conrado Roberto Hoffmann Filho
Heart Failure
Inspiratory Muscle Training in HFpEF
This study is being done to determine how inspiratory muscle training impacts inspiratory muscle function during exercise in heart failure patients.
- Trial name
- NCT06510231
- Testing
- Inspiratory Muscle Training
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Mayo Clinic
Heart Failure With Preserved Ejection Fraction, Hypertension
Clinical Significance and Diagnosis of Sarcopenia in Cardiac Patients
Obesity sarcopenia, characterized by the coexistence of excess fat and muscle mass reduction, may contribute to the pathophysiology of exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF).
- Conditions
- Heart Failure With Preserved Ejection Fraction, Hypertension, Sarcopenic Obesity
- Trial name
- NCT04175080
- Where
- Poland
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
Hypertrophic Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Use of SGLT2i in noHCM With HFpEF
This study aims to evaluate the impact of Sodium-dependent glucose transporters 2 inhibitor Empagliflozin on the exercise capacity,symptoms of heart failure, cardiac function, myocardial remodeling and quality of life of…
- Trial name
- NCT06401343
- Testing
- Empagliflozin 10 MG
- Where
- China
- Volunteers
- 94 people
- Sponsor
- China National Center for Cardiovascular Diseases
Acute Heart Failure
Acute Heart Failure With Preserved Ejection Fraction - COngestion Discharge Evaluation
The AHF-CODE preserved study is a prospective, non-randomized, monocenter study performed in patients with heart failure with preserved ejection fraction admitted for worsening heart failure.
- Trial name
- AHF-CODE-P (NCT04343430)
- Testing
- Clinical examination centered on congestion, Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography, Biological: Blood sample retrieved for biological assessment and biobanking
- Where
- France
- Volunteers
- 170 people
- Sponsor
- Central Hospital, Nancy, France
Heart Failure
Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure
The primary purpose of this mechanistic study is to evaluate the vasodilatory effects of AZD3427 in adult patients with heart failure and will be performed at approximately 2 study sites in the United Kingdom.
- Trial name
- NCT04890548
- Testing
- AZD3427
- Sponsor
- AstraZeneca
Heart Failure Preserved Ejection Fraction, Pregnancy Complications
Middle-aged Women With Adverse Pregnancy Outcomes and Heart Failure With Preserved Ejection Fraction
Due to the steady increase in the burden of HFpEF, especially in women, it is an important task to search for new markers and early predictors associated with the development of this disease.
- Trial name
- MAPO-HF (NCT06338943)
- Testing
- Echocardiography, Questionnaire
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Heart Failure With Preserved Ejection Fraction
Application of Multimodal Large Language Model in HFpEF
This study will validate the effectiveness of a multimodal large language model to screen for heart failure with preserved ejection fraction (HFpEF), comparing it with the traditional clinical standardized assessment process.
- Trial name
- MeG-HFpEF (NCT06486649)
- Testing
- Multimodal Large Language Model Diagnosis, Routine diagnostic and therapeutic procedure
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University Third Hospital
Heart Failure, Healthy Volunteer
Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
- Trial name
- NCT03276728
- Testing
- AMG 986 IV, AMG 986 PO
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Amgen